Onk Therapeutics Announces $21.5M Series A Financing To Advance Pipeline Of Next-Generation Optimally Engineered Off-The-Shelf Nk Cell Therapies
Onk Therapeutics Announces $21.5M Series A Financing To Advance Pipeline Of Next-Generation Optimally Engineered Off-The-Shelf Nk Cell Therapies
01/06/22, 9:00 AM
Money raised
$21.5 million
Round Type
series a
ONK Therapeutics, an innovative NK cell therapy platform company, today announced the closing of its $21.5 million Series A financing, led by current investors Acorn Bioventures and ALSHC, who were joined by Cormorant Asset Management.